Blog Big Molecule Watch November 19, 2019

FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)

Samsung Bioepis Co., Ltd announced today that the FDA has accepted for review an aBLA for SB8, a bevacizumab biosimilar to Roche’s Avastin® product.  If approved, SB8 will be commercialized in the US by Merck & Co.

 

The post FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8) appeared first on Big Molecule Watch.